Is ELUT or ESLA more undervalued in 2026?

CirclFi compares Elutia, Inc. (ELUT) and Estrella Immunopharma, Inc. (ESLA) using 13 institutional-grade valuation models. ELUT has a Quality of Company score of 4.7/10 while ESLA scores 3.1/10.

Which is a better buy — ELUT or ESLA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ELUT and ESLA valuations compare?

ELUT at $1.16 and ESLA at $1.09 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ELUT vs ESLA Valuation Comparison 2026 — Intrinsic Value Analysis

ELUT

Biological Products, (No Diagnostic Substances)

Elutia, Inc.

Quality

4.7

out of 10

Value Trap

WARN

Price

$1.16

Last close

Models

10/13

Active

ESLA

Biological Products, (No Diagnostic Substances)

Estrella Immunopharma, Inc.

Quality

3.1

out of 10

Value Trap

SAFE

Price

$1.09

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	ELUT Fair Value	ELUT Upside	ESLA Fair Value	ESLA Upside
Bayesian DCF	Intrinsic	$0.40	-65.6%	$0.32	-70.3%
Earnings Power Value	Intrinsic	$0.76	-24.3%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	—	—	$1.51	+35.0%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ELUT vs ESLA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ELUT vs ESLA — Which Stock Is More Undervalued?

ELUT scores higher with a 4.7/10 quality rating vs ESLA's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Elutia, Inc. (ELUT) and Estrella Immunopharma, Inc. (ESLA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ELUT currently trades at $1.16 with a QOC of 4.7/10, while ESLA trades at $1.09 with a QOC of 3.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).